Inhibition of CDK12/CDK13-CYCLIN K rewires P-TEFb signaling to reverse HIV-1 latency and modulate cellular gene expression
Open Access
- 6 October 2026
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (11) , 4558-4584
Abstract
Persistent HIV-1 latency in long-lived CD4⁺ T-cell reservoirs remains a major obstacle towards viral eradication. Current antiretroviral therapy (cART) exhibits limited clinical efficacy, highlighting the need for new therapeutic interventions. Here, we identify the CDK12/CDK13-Cyclin K (CCNK) complex as a regulator of HIV-1 latency. Pharmacological inhibition of CDK12/CDK13-CCNK with the SR-4835 inhibitor robustly reversed HIV-1 latency in the absence of additional stimuli, both in T cell models and in primary CD4⁺ T cells from people living with HIV-1 receiving cART. Targeting of CDK12/CDK13-CCNK with SR-4835 further synergized HIV-1 latency reversal and enhanced viral reactivation when co-treated with established Latency Reversal Agents. Mechanistically, CDK12/CDK13-CCNK inhibition promoted the release of P-TEFb (CDK9/CYCLIN T) from its inhibitory 7SK snRNP complex, resulting in increased recruitment of RNA polymerase II, CDK9 activation, and remodeled chromatin that overall drove productive HIV-1 transcription. Beyond HIV-1 reactivation, our findings reveal a previously unrecognized compensatory interplay between transcriptional kinases that activate gene expression, thereby rewiring cellular transcriptional programs. Together, this study identifies CDK12/CDK13-CCNK complex as a therapeutic target for HIV-1 latency reversal and provides a mechanistic rationale for improving strategies aimed at achieving an HIV cure.Keywords
Funding Information
- Israel Science Foundation (1884/24)
- Bi national Foundation (2021273)
- Deutsche Forschungsgemeinschaft (378/25)
- Germany Excellence Strategy -SynthImmune (EXC 3018/1 - 533587280)
- DFG-Emmy Noether Program (495793173)
- German Center for Infection Research
This publication has 69 references indexed in Scilit:
- Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Current progress and novel strategies that target CDK12 for drug discoveryEuropean Journal of Medicinal Chemistry, 2022
- Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerCell Reports, 2021
- CDK12: a potential therapeutic target in cancerDrug Discovery Today, 2020
- Curing HIV: Seeking to Target and Clear Persistent InfectionCell, 2020
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast CancerCancer Cell, 2019
- Between a shock and a hard place: challenges and developments in HIV latency reversalCurrent Opinion in Virology, 2019
- HIV-1 Rev Function and RNA Nuclear-Cytoplasmic Export2014
- Transcription elongation factors DSIF and NELF: Promoter-proximal pausing and beyondBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2013
- The Control of HIV Transcription: Keeping RNA Polymerase II on TrackCell Host & Microbe, 2011